Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Validation of QPOP-optimized combinations on P100v cells.
  • Fig. S2. IC50 comparison of QPOP-ranked efficacious drug combinations across different cell lines.
  • Fig. S3. QPOP-optimized drug combinations are efficacious against 7 nM Bort-resistant ALL cells.
  • Fig. S4. QPOP-optimized drug combinations are efficacious against 200 nM Bort-resistant ALL cells.
  • Fig. S5. Venn diagram showing common significant probes between three treatment groups.
  • Fig. S6. Mean weight of tumor-bearing mice for identification of optimal in vivo drug concentrations via QPOP analysis.
  • Fig. S7. Analysis of QPOP-optimal drug combination in a Bort-resistant ALL in vivo model.
  • Table S1. Top hits from the high-content screening of the FDA-approved oncology drug set at 1 μM on P100v.
  • Table S2. Top hits from the high-content screening of the FDA-approved oncology drug set at 5 μM on P100v.
  • Table S3. QPOP analysis using a design consisting of 128 combinations for 14 drugs at two levels (−1 and 1).
  • Table S4. Concentrations of drugs used for first iteration consisting of 14 drugs at two levels (1 and −1).
  • Table S5. Estimates and significance of QPOP analysis for first iteration (14 drugs at two levels).
  • Table S6. QPOP analysis using a design consisting of 155 combinations for nine drugs at three different levels (−1, 0, and 1).
  • Table S7. Concentrations of drugs used for second iteration consisting of nine drugs at three levels (1, 0, and −1).
  • Table S8. Estimates and significance of QPOP analysis for second iteration (nine drugs at three levels).
  • Table S9. Top 10 ranked QPOP-optimized two-drug combinations.
  • Table S10. Top 8 ranked QPOP-optimized three-drug combinations.
  • Table S11. Validation of Dec/MitoC on MM patient samples.
  • Table S12. Drugs and corresponding concentrations used for ex vivo QPOP.
  • Table S13. RNA sequencing pathway analysis upon treatment with 2.5 μM Dec versus DMSO control.
  • Table S14. RNA sequencing pathway analysis comparing Dec-treated and Dec/MitoC-treated P100v cells.
  • Table S15. Concentrations of Dec and MitoC used for in vivo QPOP analysis at five levels.
  • Table S16. Output used for in vivo QPOP analysis.
  • Table S17. Ranked list of in vivo QPOP drug dosage optimizations.
  • Table S18. Estimates and significance of in vivo QPOP analysis (four drugs at five levels).

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S19. Primary data from figures shown (Excel file).
  • Data file S1 (Microsoft Word format). MATLAB code for quadratic series.